Revenue
$2.16B
Fiscal year ended 2026-06-30Operating income
$72.06M
Fiscal year ended 2026-06-30Free cash flow
$152.83M
Fiscal year ended 2026-06-30ICU MEDICAL INC/DE (ICUI) reported revenue of $2.16B for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from ICU MEDICAL INC/DE’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Surgical & Medical Instruments & Apparatus.
Income
| Metric | 2026-06-30 |
|---|---|
| Revenue | $2.16B |
| Cost of revenue | Unavailable |
| Gross profit | $845.14M |
| Operating income | $72.06M |
| Net income | Unavailable |
| Research & development | $86.32M |
| Weighted-average diluted shares | Unavailable |
| Pretax income | Unavailable |
| Income tax expense | -$30.96M |
| Diluted EPS | Unavailable |
| Selling, general & administrative | $615.07M |
| General & administrative | Unavailable |
| Selling & marketing | Unavailable |
Balance
| Metric | 2026-06-30 |
|---|---|
| Cash & equivalents | Unavailable |
| Total assets | $3.97B |
| Current assets | $1.21B |
| Total liabilities | Unavailable |
| Current liabilities | $498.36M |
| Total equity incl. NCI | $2.15B |
| Temporary (mezzanine) equity | Unavailable |
| Inventory | $607.42M |
| Accounts receivable | $183.53M |
| Goodwill | $1.48B |
| Long-term debt | $1.21B |
| Accounts payable | $149.16M |
Cash flow
| Metric | 2026-06-30 |
|---|---|
| Operating cash flow | $236.37M |
| Capital expenditures | $83.54M |
| Investing cash flow | -$79.76M |
| Financing cash flow | -$154.53M |
| Net change in cash | -$1.73M |
| Stock-based compensation | $55.00M |
| Common dividends paid | Unavailable |
| Common share repurchases | Unavailable |
| Depreciation & amortization | $201.27M |
Derived
| Metric | 2026-06-30 |
|---|---|
| Free cash flow | $152.83M |
| Gross margin | 39.1% |
| Operating margin | 3.3% |
| FCF margin | 7.1% |
| SBC / revenue | 2.5% |
| Current ratio | 2.43x |
| Revenue YoY growth | -9.0% |
| Net margin | Unavailable |
| R&D / revenue | 4.0% |
| CapEx / revenue | 3.9% |
| Long-term debt / equity | 0.56x |
| Effective tax rate | Unavailable |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ICUI in the interactive workspace to inspect any figure back to its filing.
Source filings
10-Q · Filed 2026-08-06View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-02-19View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-08-07View SEC filing
10-Q · Filed 2025-05-08View SEC filing
Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.